Dr.Reddy’s Laboratories (NYSE:RDY) announced its quarterly earnings data on Wednesday. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.12, MarketWatch Earnings reports. Dr.Reddy’s Laboratories had a return on equity of 19.66% and a net margin of 11.15%. The business had revenue of $588.00 million during the quarter, compared to analysts’ expectations of $552.28 million.
Shares of RDY traded up $0.77 during trading hours on Friday, reaching $51.34. The stock had a trading volume of 4,027 shares, compared to its average volume of 218,106. The company has a quick ratio of 1.23, a current ratio of 1.81 and a debt-to-equity ratio of 0.01. Dr.Reddy’s Laboratories has a 52 week low of $33.33 and a 52 week high of $53.64. The firm has a 50-day moving average of $48.97 and a 200 day moving average of $43.07. The company has a market cap of $8.57 billion, a P/E ratio of 30.84 and a beta of 0.48.
RDY has been the topic of a number of recent analyst reports. Nomura Instinet restated a “buy” rating on shares of Dr.Reddy’s Laboratories in a report on Tuesday, April 21st. ValuEngine raised shares of Dr.Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Friday, March 13th. Finally, TheStreet cut shares of Dr.Reddy’s Laboratories from a “b” rating to a “c” rating in a research report on Monday, January 27th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $39.50.
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.
Read More: Limitations of analyzing profit margin
Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.